Filed Pursuant to Rule 424(b)(5)
Registration No. 333-186103
PROSPECTUS SUPPLEMENT
To Prospectus dated December 17, 2013
CEL-SCI CORPORATION
500,000 Shares of Common Stock
By means of this prospectus supplement, we are offering shares of our
common stock to the holders of the Series M warrants who elect to exercise the
warrants. The Series M warrants may be exercised at any time prior to April 20,
2014 at a price of $1.00 per share.
Our common stock is currently traded on the NYSE MKT (formerly known as
the NYSE Amex) under the symbol "CVM." On March 13, 2014, the closing price of
our common stock on the NYSE MKT was $1.27 per share. For a more detailed
description of our common stock and warrants, see the section entitled
"Description of Securities" beginning on page 13 of this Prospectus Supplement.
Investing in our common stock involves a high degree of risk. See "Risk
Factors" beginning on page 10 of this prospectus supplement and page 11 of the
accompanying prospectus.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 14, 2014
1
TABLE OF CONTENTS
Prospectus Supplement
Page
About this Prospectus Supplement 3
Forward-Looking Statements 4
Prospectus Supplement Summary 4
The Offering 9
Risk Factors 10
Use of Proceeds 11
Dilution 12
Description of Securities 12
Legal Matters 13
Where You Can Find More Information 13
Incorporation of Documents by Reference 14
2
ABOUT THIS PROSPECTUS SUPPLEMENT
This document is in two parts. The first part is the prospectus
supplement, including the documents incorporated by reference, which describes
the specific terms of this offering. The second part, the accompanying
prospectus, including the documents incorporated by reference, provides more
general information. Generally, when we refer to this prospectus, we are
referring to both parts of this document combined. We urge you to carefully read
this prospectus supplement and the accompanying prospectus, and the documents
incorporated herein and therein, before buying any of the securities being
offered by this prospectus supplement. This prospectus supplement may add,
update or change information contained in the accompanying prospectus. To the
extent that any statement that we make in this prospectus supplement is
inconsistent with statements made in the accompanying prospectus or any
documents incorporated by reference therein, the statements made in this
prospectus supplement will be deemed to modify or supersede those made in the
accompanying prospectus and such documents incorporated by reference therein.
You should rely only on the information contained or incorporated herein
by reference in this prospectus supplement and contained or incorporated therein
by reference in the accompanying prospectus. We have not authorized anyone to
provide you with different or additional information. We have not authorized
anyone to give any information other than that contained in the prospectus, this
prospectus supplement, and any free writing prospectus prepared by us or on our
behalf. If anyone provides you with different, additional or inconsistent
information, you should not rely on it. You should assume that the information
in this prospectus supplement and the accompanying prospectus is accurate only
as of the date on the front of the applicable document and that any information
we have incorporated by reference is accurate only as of the date of the
document incorporated by reference, regardless of the time of delivery of this
prospectus supplement or the accompanying prospectus, or any sale of a security.
Our business, financial condition, results of operations and prospects may have
changed since those dates. You should read this prospectus supplement, the
accompanying prospectus and the documents incorporated by reference in this
prospectus supplement and the accompanying prospectus when making your
investment decision. You should also read and consider the information in the
documents we have referred you to in the section of this prospectus entitled
"Additional Information."
We are offering to sell, and are seeking offers to buy, the securities
only in jurisdictions where such offers and sales are permitted. The
distribution of this prospectus supplement and the accompanying prospectus and
the offering of the securities in certain jurisdictions or to certain persons
within such jurisdictions may be restricted by law. Persons outside the United
States who come into possession of this prospectus supplement and the
accompanying prospectus must inform themselves about and observe any
restrictions relating to the offering of the securities and the distribution of
this prospectus supplement and the accompanying prospectus outside the United
States. This prospectus supplement and the accompanying prospectus do not
constitute, and may not be used in connection with, an offer to sell, or a
solicitation of an offer to buy, any securities offered by this prospectus
supplement and the accompanying prospectus by any person in any jurisdiction in
which it is unlawful for such person to make such an offer or solicitation.
This prospectus supplement, the accompanying prospectus, and the
information incorporated herein and therein by reference may include trademarks,
3
service marks and trade names owned by us or other companies. All trademarks,
service marks and trade names included or incorporated by reference into this
prospectus supplement or the accompanying prospectus are the property of their
respective owners.
In this prospectus, unless otherwise specified or the context requires
otherwise, we use the terms "CEL-SCI," the "Company," "we," "us" and "our" to
refer to CEL-SCI Corporation. Our fiscal year ends on September 30.
FORWARD-LOOKING STATEMENTS
This prospectus supplement, the accompanying prospectus and the
documents incorporated by reference herein and therein contain forward-looking
statements. These statements relate to future events and involve known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any future
results, performances or achievements expressed or implied by the
forward-looking statements.
Factors that might affect our forward-looking statements include those
disclosed in this prospectus and the accompanying prospectus.
In some cases, you can identify forward-looking statements by terms
such as "may," "will," "should," "could," "would," "expects," "plans,"
"anticipates," "believes," "estimates," "projects," "predicts," "potential" and
similar expressions intended to identify forward-looking statements. These
statements reflect our current views with respect to future events and are based
on assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements. We discuss many of these risks in greater detail under the heading
"Risk Factors" herein and in the documents incorporated by reference herein.
Also, these forward-looking statements represent our estimates and assumptions
only as of the date of the document containing the applicable statement.
Unless required by law, we undertake no obligation to update or revise
any forward-looking statements to reflect new information or future events or
developments. Thus, you should not assume that our silence over time means that
actual events are bearing out as expressed or implied in such forward-looking
statements. Before deciding to purchase our securities, you should carefully
consider the risk factors incorporated by reference and set forth herein, in
addition to the other information set forth in this prospectus supplement, the
accompanying prospectus and in the documents incorporated by reference herein
and therein.
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights certain information about us, this offering and
information appearing elsewhere in this prospectus supplement, in the
accompanying prospectus and in the documents we incorporate by reference. This
summary is not complete and does not contain all of the information that you
should consider before investing in our securities. To fully understand this
offering and its consequences to you, you should read this entire prospectus
supplement and the accompanying prospectus carefully, including the information
referred to under the heading "Risk Factors" in the accompanying prospectus and
4
set forth herein, the financial statements and other information incorporated by
reference in this prospectus supplement and the accompanying prospectus when
making an investment decision.
About CEL-SCI Corporation
We were formed as a Colorado corporation in 1983. Our principal office
is located at 8229 Boone Boulevard, Suite 802, Vienna, VA 22182. Our telephone
number is 703-506-9460 and our web site is www.cel-sci.com.
Our business consists of the following:
1) Multikine(R) (Leukocyte Interleukin, Injection) investigational
immunotherapy against cancer and Human Papilloma Virus (HPV);
2) LEAPS technology, with two investigational therapies,
LEAPS-H1N1-DC pandemic flu treatment for hospitalized patients
and CEL-2000, a rheumatoid arthritis treatment vaccine.
MULTIKINE
Our lead investigational therapy, Multikine, is currently being
developed as a potential therapeutic agent directed at using the immune system
to produce an anti-tumor immune response. Data from Phase I and Phase II
clinical trials suggest that Multikine simulates the activities of a healthy
person's immune system, enabling it to use the body's own anti-tumor immune
response. Multikine (Leukocyte Interleukin, Injection) is the full name of this
investigational therapy, which, for simplicity, is referred to in the remainder
of this document as Multikine. Multikine is the trademark that we have
registered for this investigational therapy, and this proprietary name is
subject to FDA review in connection with our future anticipated regulatory
submission for approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency. Neither has its
safety or efficacy been established for any use.
Multikine has been cleared by the regulators in ten countries around
the world, including the U.S. FDA, for a global Phase III clinical trial in
advanced primary (not yet treated) head and neck cancer patients. The trial is
currently under the management of two new clinical research organizations (CROs)
who are adding 60-80 clinical centers in existing and new countries to increase
the speed of patient enrollment.
The trial will test the hypothesis that Multikine treatment
administered prior to the current standard therapy for head and neck cancer
patients (surgical resection of the tumor and involved lymph nodes followed by
radiotherapy or radiotherapy and concurrent chemotherapy) will extend the
overall survival, enhance the local/regional control of the disease and reduce
the rate of disease progression in patients with advanced oral squamous cell
carcinoma.
The primary clinical endpoint in CEL-SCI's ongoing Phase III clinical trial
is that a 10% improvement in overall survival in the Multikine treatment arm,
plus the current standard of care (SOC - consisting of surgery + radiotherapy or
surgery + radiochemotherapy), over that which can be achieved in the SOC arm
alone (in the well-controlled Phase III clinical trial currently ongoing) must
be achieved. Based on what is presently known about the current survival
statistics for this population, CEL-SCI believes that achievement of this
endpoint should enable CEL-SCI, subject to further consultations with FDA, to
move forward, prepare and submit a Biologic License Application to FDA for
Multikine.
The clinical trial is giving immunotherapy to cancer patients, i.e.,
prior to their receiving any conventional treatment for cancer, including
surgery, radiation and/or chemotherapy. This could be shown to be important
because conventional therapy may weaken the immune system, and may compromise
the potential effect of immunotherapy. Because Multikine is given before
conventional cancer therapy, when the immune system may be more intact, we
5
believe the possibility exists for it to have a greater likelihood of activating
an anti-tumor immune response under these conditions. This likelihood is one of
the clinical aspects being evaluated in the ongoing global Phase III clinical
trial.
Multikine is a different kind of investigational therapy in the fight
against cancer. Multikine is a defined mixture of cytokines. It is a combination
immunotherapy, possessing both active and passive properties.
In October 2012 and again in November 2013, in an interim review of the
safety data from the Phase III study, an Independent Data Monitoring Committee
(IDMC) raised no safety concerns. The IDMC also indicated that no safety signals
were found that would call into question the benefit/risk of continuing the
study. CEL-SCI considers the results of the IDMC review to be important since
studies have shown that up to 30% of Phase III trials fail due to safety
considerations and the IDMC's safety findings from this interim review were
similar to those reported by investigators during CEL-SCI's Phase I-II trials.
Ultimately, the decision as to whether a drug is safe is made by the FDA based
on an assessment of all of the data from a trial.
On October 7, 2013, CEL-SCI announced a Cooperative Research and
Development Agreement with the U.S. Naval Medical Center, San Diego. Pursuant to
this agreement, the Naval Medical Center will conduct Human Subjects
Institutional Review Board approved Phase I study of CEL-SCI's investigational
immunotherapy, Multikine, in HIV/HPV co-infected men and women with peri-anal
warts. Anal and genital warts are commonly associated with the Human Papilloma
Virus, the most common sexually transmitted disease. Men and women with a
history of anogenital warts have a 30 fold increased risk of anal cancer.
Persistent HPV infection in the anal region is thought to be responsible for up
to 80% of anal cancers. HPV is a significant health problem in the HIV infected
population as individuals are living longer as a result of greatly improved HIV
medications.
The purpose of this study is to evaluate the safety and clinical impact
of Multikine as a treatment of peri-anal warts and assess its effect on anal
intraepithelial dysplasia (AIN) in HIV/HPV co-infected men and women.
CEL-SCI will contribute the investigational study drug Multikine, will
retain all rights to any currently owned technology, and will have the right to
exclusively license any new technology developed from the collaboration.
Multikine is being given to the HIV/HPV co-infected patients with peri-anal
warts since promising early results were seen in another Institutional Review
Board approved Multikine Phase I study conducted at the University of Maryland.
6
In this study, investigational therapy Multikine was given to HIV/HPV
co-infected women with cervical dysplasia resulting in visual and histological
evidence of clearance of lesions. Furthermore, elimination of a number of HPV
strains was determined by in situ polymerase chain reaction (PCR) performed on
tissue biopsy collected before and after Multikine treatment. As reported by the
investigators in the earlier study, the study volunteers all appeared to
tolerate the treatment with no reported serious adverse events.
The treatment regimen for the study of up to 15 HIV/HPV co-infected
patient volunteers with peri-anal warts to be conducted by the Naval Medical
Center will be identical to the regimen that was used in the earlier Multikine
cervical study in HIV/HPV co-infected patients.
In October 2013, CEL-SCI entered into a co-development and profit
sharing agreement with Ergomed for Multikine in HIV/HPV co-infected men and
women with peri-anal warts. This agreement will initially be in support of the
development with the US Navy. Ergomed will assume up to $3 million in clinical
and regulatory costs.
Also in October 2013, CEL-SCI entered into a co-development and profit
sharing agreement with Ergomed for Multikine in HIV/HPV co-infected women with
cervical dysplasia. Human Papilloma Virus (HPV) is the most common sexually
transmitted disease. HPV is a significant health problem in the HIV infected
population as individuals are living longer as a result of greatly improved HIV
medications. People living with HIV and others with compromised immunity are
more at risk for HPV-related complications. Persistent HPV infection can also be
a precursor to cervical cancer. Ergomed will assume up to $3 million in clinical
and regulatory costs.
CEL-SCI's focus in HPV is not the development of an antiviral against
HPV in the general population. Instead it is the development of an immunotherapy
to be used in patients who are immune suppressed by diseases such as HIV and are
therefore less able or unable to control HPV and its resultant diseases. This
group of patients has no good treatments available to them and there are, to the
Company's knowledge, no competitors at the current time. HPV is also relevant to
the head and neck cancer Phase III study since it is now known that HPV is a
cause of head and neck cancer. Multikine was shown to kill HPV in an earlier
study of HIV infected women with cervical dysplasia.
LEAPS
CEL-SCI's patented T-cell Modulation Process, referred to as LEAPS
(Ligand Epitope Antigen Presentation System), uses "heteroconjugates" to direct
the body to choose a specific immune response. LEAPS is designed to stimulate
the human immune system to more effectively fight bacterial, viral and parasitic
infections as well as autoimmune, allergies, transplantation rejection and
cancer, when it cannot do so on its own. Administered like a vaccine, LEAPS
combines T-cell binding ligands with small, disease associated, peptide antigens
and may provide a new method to treat and prevent certain diseases.
The ability to generate a specific immune response is important because
many diseases are often not combated effectively due to the body's selection of
the "inappropriate" immune response. The capability to specifically reprogram an
immune response may offer a more effective approach than existing vaccines and
drugs in attacking an underlying disease.
7
Using the LEAPS technology, we have created a potential peptide treatment
for H1N1 (swine flu) hospitalized patients. This LEAPS flu treatment is designed
to focus on the conserved, non-changing epitopes of the different strains of
Type A Influenza viruses (H1N1, H5N1, H3N1, etc.), including "swine", "avian or
bird", and "Spanish Influenza", in order to minimize the chance of viral "escape
by mutations" from immune recognition. Therefore one should think of this
treatment not really as an H1N1 treatment, but as a pandemic flu treatment.
CEL-SCI's LEAPS flu treatment contains epitopes known to be associated with
immune protection against influenza in animal models.
Additional work on this treatment for the pandemic flu work is being
pursued in collaboration with the National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health, USA. In May 2011
NIAID scientists presented data at the Keystone Conference on "Pathogenesis of
Influenza: Virus-Host Interactions" in Hong Kong, China, showing the positive
results of efficacy studies in mice of L.E.A.P.S. H1N1 activated dendritic cells
(DCs) to treat the H1N1 virus. Scientists at the NIAID found that H1N1-infected
mice treated with LEAPS-H1N1 DCs showed a survival advantage over mice treated
with control DCs. The work was performed in collaboration with scientists led by
Kanta Subbarao, M.D., Chief of the Emerging Respiratory Diseases Section in
NIAID's Division of Intramural Research, part of the National Institutes of
Health, USA.
In July 2013, CEL-SCI announced the publication of the results of
additional influenza studies by researchers from the NIAID in the Journal of
Clinical Investigation (www.jci.org/articles/view/67550). The studies described
in the publication show that when CEL-SCI's investigational J-LEAPS Influenza
Virus treatments were used "in vitro" to activate immune cells called dendritic
cells (DCs), these activated dendritic cells, when injected into influenza
infected mice, arrested the progression of lethal influenza virus infection in
these mice. The work was performed in the laboratory of Dr. Subbarao.
With our LEAPS technology, we have also developed a second peptide
named CEL-2000, a potential rheumatoid arthritis vaccine. The data from animal
studies of rheumatoid arthritis using the CEL-2000 treatment vaccine
demonstrated that CEL-2000 is an effective treatment against arthritis with
fewer administrations than those required by other anti-rheumatoid arthritis
treatments, including Enbrel(R). CEL-2000 is also potentially a more disease
type-specific therapy, is calculated to be significantly less expensive and may
be useful in patients unable to tolerate or who may not be responsive to
existing anti-arthritis therapies.
RECENT FINANCING
On December 19, 2013, we, Laidlaw & Company (UK) Ltd. and Dawson James
Securities, Inc. (the "Underwriters"), entered into an underwriting agreement
(the "Underwriting Agreement") to issue and sell 4,761,905 shares of our common
stock, as well as warrants to purchase an additional 4,761,905 shares of common
stock. Each share of common stock is being sold together with a warrant to
purchase one share for the combined purchase price of $0.63, minus underwriting
discounts and commissions. We granted the Underwriters an option to purchase up
to 476,190 additional shares of common stock and/or warrants to purchase up to
476,190 additional shares of common stock, for the combined purchase price of
$0.63 for one share and one warrant, minus underwriting discounts and
8
commissions, or the separate purchase prices per share or warrant, as
applicable, set forth in the Underwriting Agreement. The option was exercisable,
in whole or in part, for a period of 45 days after December 19, 2013.
On December 23, 2013, the Underwriters exercised their over-allotment
option to purchase shares of common stock and 476,190 warrants. The offering of
the 5,238,095 shares and the 5,238,095 warrants, which includes the 476,190
shares and warrants sold as a result of the exercise of the Underwriter's
over-allotment option, closed on December 24, 2013. The net proceeds to us from
the sale of the shares, warrants and over-allotment shares and warrants was
approximately $2,989,000, after deducting the underwriting discount.
The shares and warrants were offered and sold pursuant to our existing
shelf registration statement on Form S-3 (333-186103) that was declared
effective by the Securities and Exchange Commission on February 28, 2013, a
Prospectus dated December 17, 2013 and a Prospectus Supplement dated December
19, 2013.
THE OFFERING
Common stock offered By means of this prospectus supplement we are offering
500,000 shares of our common stock to the holders of
the Series M warrants. The Series M warrants may be
exercised at any time prior to April 20, 2014 at a
price of $1.00 per share.
Use of proceeds We estimate that our net proceeds from this offering,
assuming all 500,000 Series M warrants are exercised,
will be approximately $490,000 after deducting
estimated offering expenses.
We intend to use the net proceeds from this offering
primarily for our Phase III clinical trial, other
research and development, and general and
administrative expenses.
Risk factors You should carefully read and consider the information
beginning on page 10 of this prospectus supplement and
page 11 of the accompanying prospectus set forth under
the headings "Risk Factors" and all other information
set forth in this prospectus supplement, the
accompanying prospectus, and the documents incorporated
herein and therein by reference before deciding to
invest in our common stock.
Trading symbols:
Common Stock - NYSE MKT CVM
Series S Warrants -
NYSE MKT CVM WS
Unless we indicate otherwise, the number of shares to be outstanding after
this offering is based on 55,988,015 shares of our common stock
9
outstanding as of March 10, 2014, but excludes approximately 43,617,000 shares
which may be issued upon the exercise of outstanding options and warrants or the
conversion of a note.
RISK FACTORS
Investing in our common stock involves significant risks. You should
carefully consider the "Risk Factors" included and incorporated by reference in
the accompanying prospectus, this prospectus supplement and any other applicable
prospectus supplement, including the risk factors incorporated by reference from
our most recent Annual Report on Form 10-K for the fiscal year ended September
30, 2013, filed with the SEC on December 27, 2013, as updated by our Quarterly
Reports on Form 10-Q and our other filings with the SEC, filed after the Annual
Report. The risks and uncertainties we described are not the only ones facing
us. Additional risks not presently known to us, or that we currently deem
immaterial, may also impair our business operations. If any of these risks were
to occur, our business, financial condition, or result of operations would
likely suffer. In that event, the trading price of our common stock would
decline, and you could lose all or part of your investment.
Risks related to this Offering
Management will have broad discretion as to the use of the proceeds of this
offering.
We currently intend to use the net proceeds from this offering for our
Phase III clinical trial, other research and development, and general and
administrative expenses. We have not designated the amount of net proceeds we
will receive from this offering for any particular purpose. Accordingly, our
management will have broad discretion as to the application of these net
proceeds and could use them for purposes other than those contemplated at the
time of this offering. You will be relying on the judgment of our management
with regard to the use of these net proceeds, and you will not have the
opportunity, as part of your investment decision, to assess whether the net
proceeds are being used appropriately. It is possible that the net proceeds will
be invested in a way that does not yield a favorable, or any, return for us. The
failure of our management to use such funds effectively could have a material
adverse effect on our business, financial condition, operating results and cash
flow.
You will experience immediate and substantial dilution.
Since the exercise price of the Series M warrants offered pursuant to this
prospectus supplement and the accompanying prospectus is higher than the net
tangible book value per share of our common stock, you will suffer substantial
dilution in the net tangible book value of the common stock you purchase in this
offering. After giving effect to the sale of 500,000 shares of common stock upon
the exercise of our Series M Warrants, at a price of $1.00 per share, if you
purchase securities in this offering, you will suffer immediate and substantial
dilution share in the net tangible book value of the common stock you acquire.
See the "Dilution" section of this prospectus supplement for a more detailed
discussion of the dilution you will incur if you purchase securities in this
offering.
10
You may experience future dilution as a result of future equity offerings or
other equity issuances.
We expect that significant additional capital will be needed in the
future to continue our planned operations. To raise additional capital, we may
in the future offer additional shares of our common stock or other securities
convertible into or exchangeable for our common stock. We cannot assure you that
we will be able to sell shares or other securities in any other offering at a
price per share that is equal to or greater than the price per share paid by
investors in this offering. The price per share at which we sell additional
shares of our common stock or other securities convertible into or exchangeable
for our common stock in future transactions may be higher or lower than the
price per share in this offering. To the extent we raise additional capital by
issuing equity securities, our stockholders may experience substantial dilution.
If we sell common stock, convertible securities or other equity securities, your
investment in our common stock will be diluted. These sales may also result in
material dilution to our existing shareholders, and new investors could gain
rights superior to our existing shareholders.
Our outstanding options and warrants may adversely affect the trading price of
our common stock.
As of March 10, 2014, there were outstanding options which allows the
holders to purchase approximately 6,000,000 shares of our common stock, at
prices ranging between $0.68 and $20.00 per share, outstanding warrants which
allow the holders to purchase approximately 37,341,000 shares of our common
stock, at prices ranging between $0.53 and $17.50 per share, and a convertible
note which allows the holder to acquire approximately 276,000 shares of our
common stock at a conversion price of $4.00. The outstanding options and
warrants could adversely affect our ability to obtain future financing or engage
in certain mergers or other transactions, since the holders of options and
warrants can be expected to exercise them at a time when we may be able to
obtain additional capital through a new offering of securities on terms more
favorable to us than the terms of the outstanding options and warrants. For the
life of the options, warrants and the convertible note, the holders have the
opportunity to profit from a rise in the market price of our common stock
without assuming the risk of ownership. The issuance of shares upon the exercise
of outstanding options and warrants, or the conversion of the note, will also
dilute the ownership interests of our existing stockholders.
USE OF PROCEEDS
We intend to use the net proceeds from this offering primarily for our
Phase III clinical trial, other research and development, and general and
administrative expenses. We have not yet determined the amount of net proceeds
to be used specifically for any of the foregoing purposes. The net proceeds from
this offering will not be sufficient to complete clinical trials and other
studies required for the approval of any product by the FDA, and we will need
significant additional funds in the future.
Our management will have broad discretion in the application of the
net proceeds from this offering, and investors will be relying on the judgment
of our management with regard to the use of these net proceeds. Pending the use
of the net proceeds from this offering as described above, we intend to invest
the net proceeds in short-term, investment-grade, interest-bearing instruments.
11
DILUTION
If you exercise your Series M warrants, your interest will be diluted to
the extent of the difference between the exercise price of the Series M Warrants
($1.00) and the net tangible book value per share of our common stock at the
time you sell your warrants.
The net tangible book value of our common stock on December 31, 2013 was
approximately $0.27 per share, based on 55,852,991 shares of our common stock
outstanding as of December 31, 2013. Net tangible book value per share
represents the amount of our total tangible assets, less our total liabilities,
divided by the total number of shares of our common stock outstanding. Dilution
in net tangible book value per share to new investors represents the difference
between the amount per share paid by purchasers for shares in this offering and
the net tangible book value per share of our common stock immediately
afterwards.
Assuming all 500,000 Series M Warrants are exercised (of which there is no
assurance), our as-adjusted net tangible book value as of December 31, 2013
would have been approximately $15,603,000, (unaudited) or $0.28 per share. This
represents an immediate increase in the net tangible book value of $0.01 per
share to existing stockholders and the immediate dilution in the net tangible
book value of $0.72 per share to investors purchasing our shares in this
offering.
The following table illustrates this per share dilution. All amounts in the
table are unaudited.
Exercise price of Series M warrants $1.00
Net tangible book value per share as of December 31, 2013 $0.27
As-adjusted net tangible book value per share as of
December 31, 2013, after giving effect to this offering $0.28
Increase in net tangible book value per share attributable
to this offering $0.01
Dilution per share to investors in this offering $0.72
The above discussion and table assume all Series M warrants are exercised,
and are based on 55,852,992 shares of our common stock outstanding as of
December 31, 2013 and excludes approximately 43,497,542 shares of common stock
issuable upon the full exercise of outstanding options and warrants or the
conversion of a note.
DESCRIPTION OF SECURITIES
In this offering, we are offering 500,000 shares of common stock issuable
upon the exercise of our Series M warrants. The Series M warrants have an
exercise price of $1.00 per share and expire on April 20, 2014.
12
Common stock
The material terms and provisions of our common stock are described
under the caption "Description of Securities" in the accompanying prospectus.
Our common stock is listed on the NYSE MKT under the symbol "CVM".
Options/Warrants/Convertible Note
See the "Comparative Share Date" section of our prospectus dated
December 17, 2013 for information concerning the terms of our outstanding
options, warrants and a convertible note.
Rights Agreement
In November 2007 we declared a dividend of one Series A Right and one
Series B Right for each share of our common stock which was outstanding on
November 9, 2007. When the Rights become exercisable, each Series A Right will
entitle the registered holder, subject to the terms of a Rights Agreement, to
purchase from us one share of our common stock at a price equal to 20% of the
market price of our common stock on the exercise date, although the price may be
adjusted pursuant to the terms of the Rights Agreement. If after a person or
group of affiliated persons has acquired 15% or more of our common stock or
following the commencement of, a tender offer for 15% or more of our outstanding
common stock (i) we are acquired in a merger or other business combination and
we are not the surviving corporation, (ii) any person consolidates or merges
with us and all or part of our common shares are converted or exchanged for
securities, cash or property of any other person, or (iii) 50% or more of our
consolidated assets or earning power are sold, proper provision will be made so
that each holder of a Series B Right will thereafter have the right to receive,
upon payment of the exercise price of $100 (subject to adjustment), that number
of shares of common stock of the acquiring company which at the time of such
transaction has a market value that is twice the exercise price of the Series B
Right.
LEGAL MATTERS
The validity of the issuance of the securities offered hereby will be
passed upon for us by Hart & Hart LLC, Denver, Colorado.
WHERE YOU CAN FIND MORE INFORMATION
This prospectus supplement and the accompanying prospectus are part of the
registration statement on Form S-3 we filed with the Securities and Exchange
Commission, or SEC, under the Securities Act, and do not contain all the
information set forth in the registration statement. Whenever a reference is
made in this prospectus supplement or the accompanying prospectus to any of our
contracts, agreements or other documents, the reference may not be complete, and
you should refer to the exhibits that are a part of the registration statement
or the exhibits to the reports or other documents incorporated by reference into
this prospectus supplement and the accompanying prospectus for a copy of such
contract, agreement or other document. You may inspect a copy of the
registration statement, including the exhibits and schedules, without charge, at
the SEC's public reference room mentioned below, or obtain a copy from the SEC
upon payment of the fees prescribed by the SEC.
13
We are subject to the requirements of the Securities Exchange Act of l934
and are required to file reports, proxy statements and other information with
the Securities and Exchange Commission. Copies of any such reports, proxy
statements and other information filed by us can be read and copied at the
Commission's Public Reference Room at 100 F. Street, N.E., Washington, D.C.
20549. The public may obtain information on the operation of the Public
Reference Room by calling the Commission at 1-800-SEC-0330. The Commission
maintains an Internet site that contains reports, proxy and information
statements, and other information regarding us. The address of that site is
http://www.sec.gov.
You can find information about the Company on our website at
http://www.cel-sci.com. Information found on our website is not part of this
prospectus.
INCORPORATION OF DOCUMENTS BY REFERENCE
We incorporate by reference the filed documents listed below, except as
superseded, supplemented or modified by this prospectus, and any future filings
we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the
Exchange Act (unless otherwise noted, the SEC file number for each of the
documents listed below is 001-11889):
o Annual Report on Form 10-K for the fiscal year ended September 30,
2013.
o Report on Form10-Q for the three months ended December 31, 2013.
o Current Reports on Form 8-K, which were filed with the SEC on, October
10, 2013, October 11, 2013, November 1, 2013, December 19, 2013 and
December 24, 2013.
All documents filed with the Commission by us pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this
prospectus and prior to the termination of this offering shall be deemed to be
incorporated by reference into this prospectus and to be a part of this
prospectus from the date of the filing of such documents. Any statement
contained in a document incorporated or deemed to be incorporated by reference
shall be deemed to be modified or superseded for the purposes of this prospectus
to the extent that a statement contained in this prospectus or in any
subsequently filed document which also is or is deemed to be incorporated by
reference in this prospectus modifies or supersedes such statement. Such
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this prospectus.
14
We will provide, without charge, to each person to whom a copy of this
prospectus is delivered, including any beneficial owner, upon the written or
oral request of such person, a copy of any or all of the documents incorporated
by reference below (other than exhibits to these documents, unless the exhibits
are specifically incorporated by reference into this prospectus). Requests
should be directed to:
CEL-SCI Corporation
8229 Boone Blvd., #802
Vienna, Virginia 22182
(703) 506-9460
15